Shinsuke Nakagawa

Dr. Shinsuke Nakagawa

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Yoichi MorofujiYoichi Morofuji
Yoichi Morofuji
SNShinsuke Nakagawa
Shinsuke Nakagawa
KUKenta Ujifuku
Kenta Ujifuku
TFTakashi Fujimoto
Takashi Fujimoto
KOKaishi Otsuka
Kaishi Otsuka
KTKeisuke Tsutsumi
Keisuke Tsutsumi
The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, also known as statins, are administered as first-line therapy for hypercholesterolemia, both as primary and secondary prevention. Besides the lipid-lowering effect, statins have been suggested to inhibit the development of cardiovascular disease through anti-inflammatory, antioxidant, vascular endothelial function-improving, plaque-stabilizing, and platelet aggregation-inhibiting effects. The preventive effect of statins on atherothrombotic stroke has been well established, but statins can influence other cerebrovascular diseases. This suggests that statins have many neuroprotective effects in addition to lowering cholesterol. Furthermore, research suggests that statins cause pro-apoptotic, growth-inhibitory, and pro-differentiation effects in various malignancies. Preclinical and clinical evidence suggests that statins inhibit tumor growth and induce apoptosis in specific cancer cell types. The pleiotropic effects of statins on cardiovascular and cerebrovascular diseases have been well established; however, the effects of statins on cancer patients have not been fully elucidated and are still controversial. This review discusses the recent evidence on the effects of statins on cardiovascular and cerebrovascular diseases and cancer. Additionally, this study describes the pharmacological action of statins, focusing on the aspect of ‘beyond lipid-lowering’.

11 December 2015 in Journal of Molecular Neuroscience
Verified
Journal Article
Closed access
PDF file
SFShuji Fukuda
Shuji Fukuda
SNShinsuke Nakagawa
Shinsuke Nakagawa
RTRie Tatsumi
Rie Tatsumi
Yoichi MorofujiYoichi Morofuji
Yoichi Morofuji
TTTomonori Takeshita
Tomonori Takeshita
MNMasami Niwa
Masami Niwa

4 December 2019 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
SNShinsuke Nakagawa
Shinsuke Nakagawa
JAJun Aruga
Jun Aruga

7 December 2012 in Cellular and Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
SHShoji Horai
Shoji Horai
SNShinsuke Nakagawa
Shinsuke Nakagawa
KTKunihiko Tanaka
Kunihiko Tanaka
Yoichi MorofujiYoichi Morofuji
Yoichi Morofuji
PCPierre-Oliver Couraud
Pierre-Oliver Couraud
MNMasami Niwa
Masami Niwa

1 July 2018 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
KMKayo Masago
Kayo Masago
YKYasuyuki Kihara
Yasuyuki Kihara
KYKeisuke Yanagida
Keisuke Yanagida
FHFumie Hamano
Fumie Hamano
SNShinsuke Nakagawa
Shinsuke Nakagawa
TSTakao Shimizu
Takao Shimizu

3 June 2022 in Fluids and Barriers of the CNS
Verified
Journal Article
Open access
PDF file
KSKei Sato
Kei Sato
SNShinsuke Nakagawa
Shinsuke Nakagawa
Yoichi MorofujiYoichi Morofuji
Yoichi Morofuji
YMYuki Matsunaga
Yuki Matsunaga
TFTakashi Fujimoto
Takashi Fujimoto
TMTakayuki Matsuo
Takayuki Matsuo
Background: Cerebral infarction accounts for 85% of all stroke cases. Even in an era of rapid and effective recanalization using an intravascular approach, the majority of patients have poor functional outcomes. Thus, there is an urgent need for the development of therapeutic agents to treat acute ischemic stroke. We evaluated the effect of fasudil, a Rho kinase inhibitor, on blood brain barrier (BBB) functions under normoxia or oxygen–glucose deprivation (OGD) conditions using a primary cell-based in vitro BBB model. Methods: BBB models from rat primary cultures (brain capillary endothelial cells, astrocytes, and pericytes) were subjected to either normoxia or 6 h OGD/24 h reoxygenation. To assess the effects of fasudil on BBB functions, we evaluated real time impedance, transendothelial electrical resistance (TEER), sodium fluorescein permeability, and tight junction protein expression using western blotting. Lastly, to understand the observed protective mechanism on BBB functions by fasudil we examined the role of cyclooxygenase-2 and thromboxane A2 receptor agonist U-46619 in BBB-forming cells. Results: We found that treatment with 0.3–30 µM of fasudil increased cellular impedance. Fasudil enhanced barrier properties in a concentration-dependent manner, as measured by an increased (TEER) and decreased permeability. Fasudil also increased the expression of tight junction protein claudin-5. Reductions in TEER and increased permeability were observed after OGD/reoxygenation exposure in mono- and co-culture models. The improvement in BBB integrity by fasudil was confirmed in both of the models, but was significantly higher in the co-culture than in the monoculture model. Treatment with U-46619 did not show significant changes in TEER in the monoculture model, whereas it showed a significant reduction in TEER in the co-culture model. Fasudil significantly improved the U-46619-induced TEER reduction in the co-culture models. Pericytes and astrocytes have opposite effects on endothelial cells and may contribute to endothelial injury in hyperacute ischemic stroke. Overall, fasudil protects the integrity of BBB both by a direct protective effect on endothelial cells and by a pathway mediated via pericytes and astrocytes. Conclusions: Our findings suggest that fasudil is a BBB-protective agent against acute ischemic stroke.